Teva Pharmaceutical Industries Ltd. (TEVA) stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy, duvakitug, for the treatment of inflammatory bowel diseases (IBD) such as Ulcerative Colitis and Crohn's disease.
The Phase 2b RELIEVE UCCD study, conducted in collaboration with Sanofi (SNY), met its primary endpoints for both diseases. For Ulcerative Colitis, up to 47.8% of patients receiving the high dose of duvakitug achieved clinical remission, compared to 20.45% for placebo. In the Crohn's disease group, up to 47.8% of patients on the high dose achieved endoscopic response, versus 13% for placebo.
Buoyed by these positive results, which analysts highlighted as exceeding investor expectations, several firms raised their price targets on Teva stock. Barclays lifted its target to $28 from $25, while UBS increased its target to $28 from $26, citing duvakitug's potential and Teva's potential sale of its active pharmaceutical ingredients business as potential catalysts for further upside in 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。